{
    "Trade/Device Name(s)": [
        "A-LYTE\u00ae Integrated Multisensor (IMT Na K Cl)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K222438",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151767"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JGS",
        "CEM",
        "CGZ"
    ],
    "Summary Letter Date": "January 31, 2023",
    "Summary Letter Received Date": "February 1, 2023",
    "Submission Date": "July 20, 2023",
    "Regulation Number(s)": [
        "21CFR862.1665",
        "21CFR862.1170",
        "21CFR862.1600"
    ],
    "Regulation Name(s)": [
        "Sodium Test System",
        "Chloride Test System",
        "Potassium Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Sodium",
        "Potassium",
        "Chloride"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (lithium heparin)",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Atellica\u00ae CI Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Indirect potentiometric measurement",
        "Integrated Multisensor Technology (IMT)"
    ],
    "Methodologies": [
        "Ion-selective electrode",
        "Potentiometry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Sensor",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for A-LYTE Integrated Multisensor (IMT Na K Cl) for quantitative determination of sodium, potassium, and chloride using the Atellica CI Analyzer",
    "Indications for Use Summary": "For in vitro diagnostic quantitative determination of sodium, potassium, and chloride in human serum, plasma (lithium heparin), and urine to aid in diagnosing and treating disorders of electrolyte imbalance and metabolic conditions using the Atellica CI Analyzer",
    "fda_folder": "Clinical Chemistry"
}